Merck & Co.

Related Content

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone

News | FDA

FDA Approves Merck’s WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

March 27, 2024 — Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug ...

March 27, 2024

Application based on clinically meaningful results from the Phase 3 STELLAR trial

News | Cardiovascular Clinical Studies

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

September 28, 2023

Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date

News | Cardiovascular Clinical Studies

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

September 12, 2023

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick look back in heart history at four individuals who earned their place in the National Inventors Hall of Fame

Feature | Cardiovascular Business| By Christine Book

At the Intersection of History and Heart Health: Inventors Hall of Fame Inductees

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick ...

August 18, 2022

FDA clears Verquvo, Vericiguat, Heart failure drug.

News | Heart Failure

FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization

January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat). It is the first ...

January 25, 2021

$Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio$

News | Heart Failure

Vericiguat Improves Outcomes in Patients with Worsening Heart Failure

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational ...

March 29, 2020

News | Pharmaceuticals

Merck Announces Results of REVEAL Outcomes Study of Anacetrapib

September 11, 2017 — Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the ...

September 11, 2017

News | Hypertension

Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study

July 5, 2017 — Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of ...

July 05, 2017

Merck, IMPROVE-IT, results, New England Journal of Medicine, NEJM, Vytorin

News | Pharmaceuticals

New England Journal of Medicine Publishes Vytorin IMPROVE-IT Study Results

June 17, 2015 - Merck announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial ...

June 17, 2015

News

Post-Hoc Analyses of TRA-2°P Trial Show Efficacy of Zontivity with Aspirin and Clopidogrel

March 6, 2015 — Merck announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist ...

March 06, 2015